A draft bill circulating in the House of Representatives has yielded clues about the final form new OTC regulation may take. Though still early in the process, there seems to be a willingness among senators to exempt end users, particularly non-financial firms, from mandatory central clearing. Such exemption, while to the advantage of many businesses, has the potential to segment the market and could lead to price discrepancies.